Navigation Links
PDI Reports 2012 Fourth Quarter and Year End Financial Results
Date:3/6/2013

rations$
(1.64)$
(0.13)$
(1.75)$
(0.26)CEO CommentsCommenting on the results, Nancy Lurker, chief executive officer of PDI, Inc. noted, "As anticipated and discussed during the third quarter conference call, revenue for the full year of 2012 was below that of 2011, due primarily to the timing and implementation of new contracts. During 2012 we won more than $250 million in new multi-year contracts and renewals; however, as a result of the timing of these wins and the execution timelines of these contracts, only $40 million impacted revenue in 2012. Looking forward to 2013, we expect revenues to be significantly higher as we continue to gain new business and realize revenue from the 2012 wins.

"The gross margin percentage for the full year of 2012 was essentially flat compared to 2011, but, as we previously discussed, due to intensified competitive pressures, is expected to decline in 2013 as new wins with lower margins are executed. From an operating standpoint, we maintained tight cost controls. For the full year of 2012, excluding asset impairment and facilities realignment charges we reduced ongoing compensation expense and other SG&A by approximately $6.4 million compared to 2011 and the Adjusted Operating Loss, which also excludes these charges, was $1.0 million. We also had positive Adjusted EBITDA of $2.8 million for the full year of 2012. Both of these measures were improvements compared to 2011."

Ms. Lurker continued, "We entered 2013 with a strong backlog of business under contract and expect our core business to generate significantly higher revenues during the year. Because these higher revenues will generate lower overall margins we will continue to maintain tight controls over ongoing operating expenses. In addition to being a year of revenue growth for PDI, 2013 will also be a year of investment. Given the dynamics of our current core businesses we are committed to continuing to differentiate them and to developing more p
'/>"/>

SOURCE PDI, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. MGC Diagnostics Corporation Reports 2013 First Fiscal Quarter Operating Results
2. Nephros Reports 2012 Fourth Quarter and Full Year Financial Results
3. ECRI Institute PSO Offers Key Reports on Health IT and Medication Safety for Patient Safety Awareness Week
4. Optimer Reports Fourth Quarter and Fiscal Year 2012 Financial Results
5. Nektar Therapeutics Reports Fourth Quarter and Year-End 2012 Financial Results
6. IRIDEX Reports Record 2012 Fourth Quarter Results
7. Cumberland Pharmaceuticals Reports 2012 Annual Financial Results
8. On-Demand Reports on Partnering Terms in Healthcare & Pharma Sectors: New Market Research at ReportsnReports.com
9. Isis Reports Financial Results and Highlights for 2012
10. NxStage Reports Record Fourth Quarter and Full-Year 2012 Financial Results
11. Valeant Pharmaceuticals Reports 2012 Fourth Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... 2014  The National Association of Drug Diversion ... by Kentucky,s real-time, stop-sale ... National Precursor Log Exchange (NPLEx) system automatically blocks ... and helps flag meth offenders for law enforcement. ... NPLEx "watch lists" that notify them via email ...
(Date:10/25/2014)... 2014 Burzynski Research Institute, Inc. (BRI) announced ... has given the company permission to conduct an open-label ... 3 months of age with a diffuse intrinsic brainstem ... of five treatment groups based on their age and ... DIPG. The primary study endpoint is a decrease in ...
(Date:10/22/2014)... N.J. , Oct. 22, 2014  Rescheduling ... major transformation in the pain market, according to ... Insights, Inc., a firm providing market research and ... Photo - http://photos.prnewswire.com/prnh/20141021/153440 ... scheduling change for hydrocodone combination products from Schedule ...
Breaking Medicine Technology:Kentucky's NPLEx Technology Making Significant Progress 2Burzynski Research Institute, Inc. Announces FDA Permission to Launch a New Clinical Trial in Diffuse Intrinsic Brainstem Glioma 2Hydrocodone: Rescheduled, Repositioned & Reinvented 2Hydrocodone: Rescheduled, Repositioned & Reinvented 3
... will be presented at the American College of,Cardiology's ... 2007 /PRNewswire-FirstCall/ -- CV,Therapeutics, Inc. announced today that ... study of ranolazine shows there was no,adverse trend ... study did not meet the primary efficacy endpoint. ...
... in Intestinal Adenomas Suggesting,Possible Beneficial Mediation in the ... 07, 2007 /PRNewswire/ -- NutraCea,announced today the results ... bran,on the number of intestinal adenomas in cancerous ... of the prestigious British,Journal of Cancer conducted at ...
Cached Medicine Technology:CV Therapeutics Announces Topline MERLIN TIMI-36 Results 2CV Therapeutics Announces Topline MERLIN TIMI-36 Results 3British Journal of Cancer Reports Preclinical Evidence of Positive,Effect of Rice Bran on Intestinal Cancer 2British Journal of Cancer Reports Preclinical Evidence of Positive,Effect of Rice Bran on Intestinal Cancer 3British Journal of Cancer Reports Preclinical Evidence of Positive,Effect of Rice Bran on Intestinal Cancer 4
(Date:10/25/2014)... Background: , In 1998 Bob Savage founded ... pioneer in the field of establishing recovery community organizations. ... and when he retired, he set out to answer a ... , 1. Where are the people in ... , 2. Can the recovery community be organized to advocate ...
(Date:10/25/2014)... 25, 2014 Homeowners that are wondering ... bad’ need wonder no more. Clean Crawls gives ... watch out for when it comes to insulation in ... the article released by Clean Crawls, can cause problems ... any insulation that has deteriorated, become damp, or been ...
(Date:10/25/2014)... Steven Reinberg HealthDay Reporter ... virus that causes common cold sores -- herpes simplex -- ... Swedish researchers suggest. In fact, being a carrier of ... Alzheimer,s disease, the researchers found. "The identification of ... disorder is a breakthrough," said lead researcher Dr. Hugo Lovheim, ...
(Date:10/25/2014)... By Randy Dotinga ... -- As more genetic tests are developed that spot increased ... would be more proactive about getting screened. But a ... does not change behavior: People who found out their genes ... than people with average risk to get screened. "It ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 ... staffing company, is happy to announce that our ... to Staffing Industry Analysts’ Staffing 100 for 2014. ... the “100 most influential people in the staffing ... Medical Solutions, the 13th-largest healthcare staffing company in ...
Breaking Medicine News(10 mins):Health News:CCAR Accepting Nominations for the Bob Savage Recovery Advocate of the Year Award 2Health News:5 Signs Indicating That Insulation Needs Replacing as Told By Clean Crawls in Recent Article 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 3Health News:Knowing Genetic Risk for Cancer May Not Change Behavior 2Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 2Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 3
... take medication to manage their symptoms of attention deficit ... ADHD - partially because the process can be so ... to simplify things with expert explanations of popular ADD ... YORK, May 27 ADDitude magazine, the ...
... 27, 2009 The Translational Genomics Research Institute (TGen) ... million to research pancreatic cancer, Stand Up to Cancer ... Physician-In-Chief, and Dr. Craig B. Thompson, Director of the ... pancreatic cancer "Dream Team, which will lead a three-year ...
... May 27 PRA International, a leading Clinical ... Center in its Sao Paulo, Brazil office. Drug Safety ... Risk Management unit. They are staffed with drug safety ... Adverse Drug Reaction management. Furthermore, our drug safety ...
... The Providence Service Corporation (Nasdaq: PRSC ... the proxy statement filed last week by the Avalon ... that the Avalon Group,s proxy statement contains numerous false ... necessary for it to correct the public record with ...
... include worries about family,s reaction, study finds , , WEDNESDAY, ... reaction to their depression is a major reason why ... In the study, which included 368 teens and one ... teens had been diagnosed with depression. The teens and ...
... CLINTON, N.J., May 27 The Sage Group, a ... that HemispherX Biopharma has expanded the mandate for The ... partnering efforts related to Ampligen (an experimental immunotherapeutic) for ... to Ampligen,s use to increase the effectiveness of preventative ...
Cached Medicine News:Health News:ADHD Treatment Guide: How to Safely, Effectively Use Medications and Non-Drug Therapies to Treat Attention Deficit Disorder 2Health News:$18 million awarded to TGen and University of Pennsylvania for pancreatic cancer research 2Health News:$18 million awarded to TGen and University of Pennsylvania for pancreatic cancer research 3Health News:$18 million awarded to TGen and University of Pennsylvania for pancreatic cancer research 4Health News:$18 million awarded to TGen and University of Pennsylvania for pancreatic cancer research 5Health News:PRA International Opens Additional Drug Safety Center in Sao Paulo, Brazil 2Health News:PRA International Opens Additional Drug Safety Center in Sao Paulo, Brazil 3Health News:Providence Service Corporation Rebuts False and Misleading Statements Contained in Proxy Statement Filed by the Avalon Group 2Health News:Providence Service Corporation Rebuts False and Misleading Statements Contained in Proxy Statement Filed by the Avalon Group 3Health News:Stigma Keeps Teens From Depression Treatment 2Health News:The Sage Group Widens Strategic Role to Assist HemispherX Biopharma in Pandemic Influenza Initiatives as Pacific Rim/Japan Treatment/Prevention Programs Accelerate 2Health News:The Sage Group Widens Strategic Role to Assist HemispherX Biopharma in Pandemic Influenza Initiatives as Pacific Rim/Japan Treatment/Prevention Programs Accelerate 3Health News:The Sage Group Widens Strategic Role to Assist HemispherX Biopharma in Pandemic Influenza Initiatives as Pacific Rim/Japan Treatment/Prevention Programs Accelerate 4
... RUBYstar enables highly sensitive time-resolved fluorescence ... cryptate fluorophores. These compounds are excited ... long fluorescence lifetimes (several hundred microseconds), ... peak profiles at 620 nm. Therefore ...
... Evolution, Tecans most advanced multi-functional microplate ... of detection performance without compromising flexibility. ... latest development on the Ultra instrument ... options which adds to the flexibility ...
... OPTIMA is a fully automated microplate ... different measurement principles:, , Fluorescence Polarization ... Fluorescence , High-Performance Luminescence (flash ... ,It is designed for the ...
... a flexible multifunction plate reader that offers ... fluorescence intensity, time-resolved fluorescence, high-perfomance luminescence and ... with injectors that deliver reagent at the ... cell assays can be performed easily and ...
Medicine Products: